Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.67 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27403102 | 0.86 | CCR5 (0.76) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL8160871 | 0.85 | CCR5 (0.69) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| Hydrochloric Acid SCHEMBL7809179 | 0.85 | CCR5 (0.74) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| Bromide SCHEMBL8163316 | 0.85 | CCR5 (0.74) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL15196646 | 0.84 | CCR5 (0.63) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL3724781 | 0.83 | CCR5 (0.66) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL8807552 | 0.82 | CCR5 (0.65) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL30353418 | 0.81 | CCR5 (0.68) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL561347 | 0.81 | CCR5 (0.68) | CCR5ALDH1A1RAB9AUSP28USP25 | |
| SCHEMBL13948892 | 0.81 | ALDH1A1 (0.77) | ALDH1A1LMNASMN1; SMN2PKMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
| CN-1468226-A | Biphenyl derivatives and their use as ppar-gamma receptor activators | �������о�����չ˽������˾ | 2004-01-14 | — | — | CN | disclosed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | CCR5 908/4885ALDH1A1 378/4885RAB9A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.